Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 20/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452481 | 1.00 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL7895537 | 1.00 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL7902704 | 1.00 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL7903215 | 1.00 | SLC6A4 (0.62) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL7901002 | 0.85 | SLC6A4 (0.65) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL7904651 | 0.85 | SLC6A4 (0.65) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL10052489 | 0.85 | SLC6A4 (0.65) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL10052492 | 0.85 | SLC6A4 (0.65) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL14983891 | 0.83 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL14983892 | 0.83 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505716-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505716-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2974724-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | Sunovion Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2393357-B1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9056830-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056830-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-8754117-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754117-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140073682-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073682-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICAL INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICAL INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8389559-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389559-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010091268-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022125-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885SLC6A2 2/4885 |
| US-20140073682-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885SLC6A2 2/4885 |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885SLC6A2 2/4885 |
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.